Iovance Biotherapeutics Inc. Stock
With only a change of -€0.005 (-0.040%) the Iovance Biotherapeutics Inc. price is nearly unchanged from yesterday.
Our community is currently high on Iovance Biotherapeutics Inc. with 19 Buy predictions and 3 Sell predictions.
As a result the target price of 25 € shows a very positive potential of 92.23% compared to the current price of 13.01 € for Iovance Biotherapeutics Inc..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Iovance Biotherapeutics Inc. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Iovance Biotherapeutics Inc. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Iovance Biotherapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc. | -0.040% | 17.799% | 4.082% | 109.285% | 66.560% | -44.518% | - |
| Ironwood Pharmaceuticals | 0.680% | 2.069% | -1.333% | -23.711% | -27.451% | -18.681% | - |
| Sage Therapeutics Inc. | 0.040% | -7.586% | -20.370% | -70.585% | -39.700% | -79.833% | - |
| Novocure Ltd | 3.840% | 25.795% | 13.841% | -76.180% | 1.121% | -90.875% | - |
Comments
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Show more
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $19.00 to $21.00. They now have a "buy" rating on the stock.
Show more
Ratings data for IOVA provided by MarketBeat
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) had its price target raised by analysts at Barclays PLC from $18.00 to $22.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for IOVA provided by MarketBeat